Trials / Recruiting
RecruitingNCT04515836
Olaparib in Patients With HRD Malignant Mesothelioma
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily. |
Timeline
- Start date
- 2021-02-19
- Primary completion
- 2028-04-15
- Completion
- 2028-04-15
- First posted
- 2020-08-17
- Last updated
- 2025-05-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04515836. Inclusion in this directory is not an endorsement.